SAGE Sage Therapeutics Inc: יחס מחיר להכנסות חזויות

Sage Therapeutics, Inc. (SAGE) relies on contract manufacturers for drug production while maintaining strict internal quality control. The issuer's forward P/S reflects the business valuation trend, with the current level sitting around 7.80. While loyalty from neurology experts previously drove scientific progress, the company is currently reducing headcount following unsuccessful trials, utilizing stock options to retain key scientists.
SAGE (Sage Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Investors are evaluating Sage Therapeutics, Inc. (SAGE) through the lens of the slow adoption of its depression drug and risks associated with Alzheimer's research, which renders revenue volatile. The forward revenue multiple on GURU.Markets compares current market capitalization with expected annual sales, allowing for a determination of whether the market is overpaying for future growth amid the company's limited cash reserves.